> daily_signal(2026_08_30)
The EPA wants to let data centers get air-pollution permits without ever telling the neighbors, as two music giants sue Anthropic, ICE moves to buy robot dogs, and an AI cancer vaccine clears Phase 3.
PickBits Daily Signal · Sunday, August 30, 2026
// tl;dr
- The EPA has proposed scrapping the Clean Air Act rule that makes states publicly post air-pollution permit applications and take comment for any source under 250 tons a year. That bracket now sweeps in the wave of new AI data centers, so one could secure its air permit with no requirement that a single neighbor ever be told. 14 states and hundreds of advocacy groups filed formal opposition.
- Sony Music Publishing and Warner Chappell sued Anthropic, alleging it torrented and scraped tens of thousands of copyrighted songs to train Claude, and named co-founders Dario Amodei and Benjamin Mann personally. They seek up to $150,000 per work and $25,000 for each stripped copyright notice. It follows the Bartz case and its $1.5 billion settlement, where a judge had already ruled that training can be fair use but acquiring the work through piracy is not.
- ICE plans to spend up to $2 million on Boston Dynamics' Spot robot dogs to enter and clear buildings ahead of its agents. The plan is public only as a procurement forecast, APFS record 75113, at roughly $75,000 each, with completion targeted for April 2027 and no award yet made.
- Merck and Moderna's individualized mRNA cancer vaccine, intismeran autogene, met both endpoints in its first Phase 3, with software picking up to 34 targets from each patient's own tumor. Earlier data had the vaccine plus Keytruda cutting recurrence-or-death by about 49% in melanoma, and the companies are now in talks with regulators.
Two of today's four are stories we've been on for weeks, and this weekend both of them moved. We've watched this EPA spend the summer clearing the road for AI data centers, from the pollution-exemption deal in July to the August pass on their power plants' limits, and this weekend it went after the piece the other two left standing: the public's right to see the permit at all. And the copyright fight we've followed since Anthropic's $1.5 billion settlement with book authors just picked up its most aggressive plaintiffs yet, with the music industry aiming the settlement's own logic back at the company and, unusually, putting the founders' names on the complaint.
The other two have nothing to do with each other, which is honestly what most days on this beat look like. ICE wants to send a robot through a front door before an agent does, and the only reason we know is a line in a federal spending forecast nobody had to announce. And an algorithm now reads a cancer patient's own tumor and writes them a vaccine for it, the first late-stage proof that a medicine designed one person at a time actually works. One of those machines is walking into somebody's house uninvited. The other is doing something no oncologist could pull off alone, and I don't mind saying the second one is the story I liked writing.
Today: the EPA moves to delete the public-comment step for data-center air permits, Sony and Warner Chappell sue Anthropic and name its founders, ICE files a forecast to buy Boston Dynamics robot dogs, and Merck and Moderna's algorithm-built cancer vaccine clears Phase 3.
1. The EPA wants to delete the step where a data center's neighbors get to see its pollution permit.
Its proposal scraps the public-notice and comment requirement for any air source under 250 tons a year, the bracket new AI data centers now fall into.
There is a point in the Clean Air Act where a state has to stop and show the public a pollution permit before it grants one. For any "minor" source, meaning anything emitting up to 250 tons of a pollutant a year, the state must post the application and hold an extended comment period. The EPA has proposed removing that requirement. The bracket is the part that matters. It was written for steel mills and concrete plants, and it now sweeps in the wave of new AI data centers, whose backup generators and turbines land many of them squarely inside it. Under the proposal, a data center could secure its air permit with no requirement that a single neighbor be notified or allowed to object.
A data center is real jobs and a real tax base, and almost nobody argues one should never be built. This isn't a new fight, and it isn't really about whether the thing gets built. It is about who gets to watch: once it is up, who is holding the receipts on what it emits, and who was allowed in the room beforehand. The administration calls it handing states discretion over public participation. That is a soft word for letting a state skip the step rather than keep it, which is why a former EPA official called the change a retreat from the agency's oldest principle: people get to see what is about to be put in their air. It's the third move we've tracked from this EPA on data centers this summer, after the July exemption deal and the August decision to spare their power plants stricter limits. What's new is that 14 states and hundreds of advocacy groups have already filed formal opposition, which, if the federal rule falls, is where the only remaining backstop lives.
Why this matters: The one tool a neighborhood has to see and contest a nearby data center's pollution is a public permit process, and this rule quietly removes it for exactly the size of facility the AI build-out is producing. Take away the notice and the comment window, and a community doesn't lose an argument. It never finds out there was one to have. My own read is that this is the most consequential of the three moves precisely because it's the least visible. Nobody can point to a comment period that was never held.
Action this week: Request the air-permit application for any data center proposed near you directly from your state environmental agency now, while the federal rule still requires them to have it on file and hand it over. Then find out whether your state has its own public-notice law that survives a federal rollback, because 14 states cared enough to oppose this in writing and a state statute may be the only thing between you and a permit granted in silence. When I have chased a document like this before, the delay was never the request. It was discovering the deadline had already passed, so start with the timeline, not the form.
bisnow.com: Trump EPA aims to kill transparency and public-feedback rules for data center emissions (August 26, 2026)
theverge.com: Trump's EPA wants to let data centers hide their air pollution (August 2026)
environmentalprotectionnetwork.org: 14 states and hundreds of groups oppose the EPA's minor-source public-notice rollback (August 20, 2026)
2. Sony Music and Warner Chappell sued Anthropic over the songs they say trained Claude.
The complaint turns on how the lyrics were acquired, by torrenting and scraping, and names co-founders Dario Amodei and Benjamin Mann as individual defendants.
If you own content, this lawsuit is about one thing, and it isn't what the AI wrote. It's whether you can prove where your catalog ended up in somebody's training data. Sony Music Publishing and Warner Chappell, the last two major music publishers to stay out of the AI copyright fight, filed suit against Anthropic on August 28 in the Northern District of California, alleging it torrented and scraped tens of thousands of copyrighted compositions, including lyrics pulled from licensed repositories like Musixmatch and LyricFind, to train Claude. They are asking for up to $150,000 per infringed work and $25,000 for every instance the company stripped copyright-management information off a file, and they named co-founders Dario Amodei and Benjamin Mann as individual defendants.
The reason the acquisition claim carries the case runs straight through Anthropic's last copyright loss. In the case that ended in its $1.5 billion settlement with book authors, the judge had already drawn the line the publishers are now standing on: training a model on copyrighted work can qualify as fair use, but obtaining that work through piracy does not. Fair use protects what you do with a book you acquired lawfully. It does not launder how you got it. I should say plainly that these are allegations, and Anthropic hasn't answered them in court yet. What is not in question is that the $25,000-per-file information-stripping theory is a template any rights-holder can now aim at any model-maker whose training pipeline discarded attribution.
Why this matters: Every company that has quietly wondered whether its content ended up in someone's training run now has a live case telling it exactly where the exposure sits, not in the model's answers but in the provenance of the data that built it. And naming two founders personally changes the math for anyone who runs an AI company or sits on its board: how the training data got collected is now something a specific person can be made to answer for, not a decision that disappears into the company.
Action this week: Get one thing into your next AI-related content contract in specific language: where your catalog sits in the counterparty's training data, and what they will attest, on the record, about how it was acquired. Point your legal team at the copyright-management-information claim in particular, because a per-instance damages theory is far easier to prove than a fair-use fight and it travels to any medium. When I have asked a vendor a sourcing question like this, the useful answer was never the reassuring sentence in the deck. It was whatever they were willing to put in writing, which is usually a great deal less.
techcrunch.com: Sony Music, Warner sue Anthropic, alleging a brazen campaign of intellectual property theft (August 29, 2026)
axios.com: Anthropic sued by Sony and Warner music over copyright (August 29, 2026)
musicbusinessworldwide.com: Sony Music Publishing and Warner Chappell sue Anthropic in multi-billion-dollar lawsuit (August 2026)
3. ICE wants to spend up to $2 million on Boston Dynamics robot dogs to walk into buildings ahead of its agents.
The plan is public only as a procurement forecast, APFS record 75113, with no award made and no hearing required.
The document is a spending forecast, not a contract, and that is the whole point. ICE has posted, in the federal Acquisition Planning Forecast System as record 75113, its intent to spend $1 to $2 million on Boston Dynamics' Spot quadruped robots, roughly $75,000 apiece, to provide "inspection, situational awareness, and hazard assessment" inside buildings before agents enter. No city voted on it. No hearing was held. It surfaced because a forecast is public, which is the only reason anyone gets to react to it at all.
To be fair, sending a machine through a doorway first can keep an agent, or a bystander, out of a lethal surprise, and Spot has done bomb-squad and hostage work for police for years. The step that got skipped is the one that turns a tool into a search. A remotely operated robot carrying cameras and sensors into a home is conducting a search whether or not a human is behind it, and the Fourth Amendment's warrant standard doesn't soften because the first thing across the threshold has four legs instead of two. This is the same surveillance build-out we flagged when ICE moved to put a face-scanning app in the hands of more than a thousand local police agencies. The difference this time is that the paperwork is visible before the purchase, not after.
Why this matters: A robot that clears a building before agents arrive is being bought on a purchasing form, which means the public conversation about whether a machine should lead an immigration raid is happening, if it happens at all, after the decision is effectively made. Procurement is where a lot of surveillance policy actually gets set now, quietly, one line item at a time, and this one is legible only because somebody read the forecast.
Action this week: Look up APFS record 75113 in the open Acquisition Planning Forecast System and, while it is still a forecast, file a public comment or a records request on the requirement before an award is signed. The leverage exists now and disappears the day the contract does, because a signed award is far harder to question than a stated intention. If you ask me, the useful fight here isn't the robot. It is insisting, on the record, that a machine crossing your threshold is still a search that needs a warrant, before that question gets answered by default.
gizmodo.com: ICE wants a Boston Dynamics K9 unit (August 29, 2026)
404media.co: ICE plans to spend millions on Boston Dynamics dog robots (August 2026)
bostonglobe.com: Boston Dynamics robot dog headed to ICE (August 29, 2026)
PickBits Daily Signal is free, and it is the fastest daily read on where AI's real costs and capabilities are landing. If it is worth something to you, the best support is to forward it to one person who would read it. Subscribe today!
4. An algorithm now reads a melanoma patient's tumor and writes them a one-of-a-kind cancer vaccine.
Merck and Moderna's intismeran autogene just cleared its first Phase 3, the first late-stage evidence that a medicine designed one patient at a time actually works.
Start with the person this is for: someone who has had a melanoma removed and now lives with a recurrence risk their oncologist won't round down. This week that risk got a real number attached to a new option. Merck and Moderna reported the first positive Phase 3 readout for an individualized cancer vaccine, intismeran autogene: software reads the mutations in a single patient's tumor, selects up to 34 of them, and encodes those targets into a bespoke mRNA shot given alongside the immunotherapy Keytruda. In the 1,137-patient INTerpath-001 trial, the combination met both of its main goals, and earlier Phase 2b data had shown it cutting recurrence-or-death by about 49% against Keytruda alone.
A Phase 3 readout isn't an approval, though, so keep three things in view. Merck and Moderna say they're only now in talks with regulators; the result is in melanoma, not every cancer; and a vaccine manufactured one patient at a time raises a real, unanswered question about who will be able to afford one. Set that against where this sits in the story we've been telling. This is the same mRNA platform that reached an FDA-approved flu vaccine earlier this month, now stretched into personalized oncology, and the neoantigen pipeline that produced this result is already in trials for lung, kidney, and bladder cancer. What I'm watching is whether the method holds up in a second cancer. That is the difference between one good melanoma trial and a real change in how a medicine gets designed.
Why this matters: For a melanoma patient who has already been through surgery, the gap between a coin-flip risk of the cancer returning and something closer to half that is the number that governs their next five years. And the reason it should interest everyone else is the method underneath it: this is the first strong evidence that letting software design a drug for a single individual, rather than for a population, produces a result a regulator might actually accept.
Action this week: Ask the treating oncologist, if melanoma has touched your family, specifically about individualized neoantigen-therapy trials or expanded access, because Merck and Moderna are moving toward a submission and trial slots are where access begins long before approval. Beyond that, watch the method rather than the drug. To me the melanoma number is almost the least interesting part; what matters is whether the same tumor-reading pipeline holds up in lung, kidney, or bladder cancer, because that is what would turn a single trial into the way a lot of medicine gets designed.
merck.com: Merck and Moderna announce Phase 3 INTerpath-001 trial met its endpoints (August 19, 2026)
statnews.com: What is in Merck and Moderna's cancer-vaccine algorithm (August 27, 2026)
modernatx.com: Phase 3 INTerpath-001 trial of intismeran plus Keytruda met RFS and DMFS endpoints in melanoma (August 2026)
» What to watch this week
- Whether the EPA finalizes the public-comment rollback, and whether the 14 opposing states pass or strengthen their own public-notice laws before it does. If the federal rule falls, a state statute is the only place a resident keeps standing to see a data center's permit.
- Whether Anthropic moves to dismiss the personal claims against Amodei and Mann, and whether other rights-holders copy the $25,000-per-file information-stripping theory. That count, not fair use, is the reusable weapon this complaint hands the next plaintiff.
- Whether ICE's forecast turns into an actual award, and whether any court or city gets a chance to weigh in on a robot conducting a warrantless building search first. APFS 75113 is where to watch it move from stated intention into signed procurement.
- Whether Merck and Moderna file for approval on the melanoma data, and whether the neoantigen pipeline's lung, kidney, and bladder trials read out the same way. A second tumor type confirming the method is what would make this more than one disease's good week.
Tomorrow's signal lands here.